News stories about Mersana Therapeutics (NASDAQ:MRSN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mersana Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.5240962738546 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Mersana Therapeutics (MRSN) opened at $15.44 on Thursday. Mersana Therapeutics has a 1-year low of $12.71 and a 1-year high of $21.01.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.13. The business had revenue of $6.27 million during the quarter, compared to analysts’ expectations of $3.93 million. equities research analysts predict that Mersana Therapeutics will post -2.9 earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $23.67.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Mersana Therapeutics (MRSN) Share Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-mersana-therapeutics-mrsn-share-price.html.
About Mersana Therapeutics
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.